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• HIV infection has been a global health issue for past three decades. Around 2
million new cases of HIV are reported every year, and if left untreated will
result in AIDS. Currently, there are no vaccines available to prevent acquisition
and transmission of HIV. Majority of HIV infections are acquired through sexual
contact. Preventative measures in the form of Pre-Exposure Prophylaxis
(PrEP) have provided an approach to reduce the sexual transmission of the
virus.
• Currently, several clinical trials are ongoing to evaluate the efficacy of local
(vaginal or rectal) delivery of anti-HIV drugs for reducing sexual transmission
of HIV infection.
• Polymeric films are being explored to enable vaginal delivery of anti-HIV drugs
for the vaginal PrEP of HIV infections.
• Adefovir dipivoxil (ADV) is an FDA-approved nucleotide reverse transcriptase
inhibitor used for the treatment of chronic HBV infections. Studies have shown
that ADV is also active against HIV-1 and HIV-2. Thus, it is possible to
“repurpose” ADV for the HIV PrEP.
INTRODUCTION
• To develop ADV containing polymeric film to enable repurposing of ADV for 
the vaginal PrEP of HIV infection
CONCLUSIONS
• Vaginal films impregnated with ADV films may be used as a vaginal
microbicide product that could effectively provide pre-exposure prophylaxis
against sexual transmission of HIV.
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• Calibration Curve of ADV in Simulated Vaginal Fluid (SVF)
A stock solution of ADV in ethanol was diluted with SVF to obtain solution
containing ADV concentration of 4, 8, 16 and 20 ppm respectively.
Absorbance of ADV solution was measured at 260.5 nm. Calibration curve
was obtained by plotting absorbance versus concentration.
• Development of Films
The placebo films were prepared by solvent casting technique. The solution
was poured into a petri plate placed on a flat surface to form a uniform layer
and air dried to form a film. The film was then carefully removed and cut into
the desired dimensions.
• Characterization of Films
The developed films were tested for organoleptic, physical, and
physiochemical properties.
• In vitro release studies
In vitro release of ADV from polymeric films was studied using a Franz
diffusion cell. Aliquots were taken at 30, 60, 120, 180, 240, 300, and 360 min
and the amount of ADV released was calculated by measuring the
absorbance.
Figure 2. In vitro 
release studies 
using Franz diffusion 
cell showed that the 
composition of the 
film had an impact 
on the release of 
ADV from the film.
Figure 1. The optimization of content of ADV in the polymeric films. ADV
content/unit surface area from right to left: 10 mg/4 cm2, 8 mg/4.5 cm2,, 5 mg/4.5
cm2, 5 mg/7.5 cm2. The quantity of ADV/unit surface area showed significant
impact on the appearance and physical properties of the film.
The films prepared with HPMC K100LV (3%) and PVP K30 (1%) as well as the 
ones with HPMC K100 LV (3%) and ethyl cellulose 7 cps (0.5%) showed 
acceptable organoleptic and physical properties.
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